MedMira to Present at FDA Meeting on Home-Use HIV Tests

Mar 08, 2006, 00:00 ET from MedMira Inc.

    HALIFAX, March 8 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira")
 (TSX Venture: MIR, NASDAQ:   MMIRF) the global market leader in premium rapid
 diagnostic solutions, announced today that it will participate in the US Food
 and Drug Administration's (FDA) Blood Products Advisory Committee (BPAC)
 meeting taking place on Friday, March 10, 2006 in Gaithersburg, Maryland. At
 the public meeting, Hermes Chan, MedMira's president and COO will present the
 company's solution for over-the-counter (OTC) home-use HIV tests to the BPAC.
     "We believe that home HIV tests can bring many benefits to both consumers
 and public health agencies in the US. More people will know their HIV status,
 seek treatment sooner, and ultimately decrease the spread of HIV," said Hermes
 Chan, president and COO, MedMira. "MedMira's solution provides a comprehensive
 OTC home-use HIV testing system, with a specific focus on public safety and
 customer value. Based on our experience in delivering OTC HIV tests to the
 Hong Kong market, we know safety and value are keys to a successful system and
 consumer experience."
     As the first rapid HIV test manufacturer in the world to launch an OTC
 test to consumers in Hong Kong in 2005, MedMira has gained significant
 experience in implementing, managing, and monitoring a system for home-use HIV
 tests. The company's MiraCare(TM) Rapid HIV Antibody Test (MiraCare(TM) HIV)
 is a highly accurate and reliable fingerstick whole blood test, based on
 MedMira's unique flow-through technology platform. This platform is the basis
 for all of MedMira's rapid tests including the FDA-approved Reveal(R) G2 Rapid
 HIV-1 Antibody test (Reveal(R) G2) which has been sold in the US since 2003.
     BPAC reviews and evaluates available data concerning the safety,
 effectiveness, and appropriate use of blood products derived from blood and
 serum or biotechnology which are intended for use in the diagnosis,
 prevention, or treatment of human diseases, and, as required, any other
 product for which the Food and Drug Administration has regulatory
 responsibility, and advises the Commissioner of Food and Drugs of its findings
 regarding the safety, effectiveness, and labeling of the products, on clinical
 and laboratory studies involving such products, on the affirmation or
 revocation of biological product licenses, and on the quality and relevance of
 FDA's research program which provides the scientific support for regulating
 these agents.
     About MedMira
     MedMira is the leading global manufacturer and marketer of in vitro flow-
 through rapid diagnostic tests. MedMira's tests provide reliable, rapid
 diagnosis in just 3 minutes for the detection of human antibodies in human
 serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
 United States FDA and the SFDA in the People's Republic of China have approved
 MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively.
     MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used
 in clinical laboratories, hospitals, and clinics where professional
 counselling and patient treatment are immediately available.
     The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter
 (OTC) in pharmacies throughout Hong Kong and Macao Special Administrative
 Regions, in the People's Republic of China. MiraCare(TM) is sold through
 MedMira's distributor network to pharmacies, hospitals and laboratories in the
 European Union.
     MedMira delivers rapid diagnostic solutions to healthcare communities
 around the globe. Its corporate offices and manufacturing facilities are
 located in Halifax, Nova Scotia, Canada with a representative office in
 Guilin, China.
     This news release contains forward-looking statements, which involve risk
 and uncertainties and reflect the company's current expectation regarding
 future events. Actual events could materially differ from those projected
 herein and depend on a number of factors including, but not limited to,
 changing market conditions, successful and timely completion of clinical
 studies, uncertainties related to the regulatory approval process,
 establishment of corporate alliances and other risks detailed from time to
 time in the company quarterly filings.
     The TSX Venture Exchange has not reviewed and does not accept
     responsibility for the adequacy or accuracy of this statement.
     For more information visit MedMira's website at

SOURCE MedMira Inc.